Alembic Pharmaceuticals receives EIR from USFDA for oncology formulation facility

With this, for all our USFDA facilities, EIRs are in place

Alembic Pharmaceuticals appoints Manish Kejriwal as Independent Director

USFDA conducts inspection at Alembic Pharmaceuticals' Panelav oncology formulation facility

The company will provide comprehensive response to USFDA for the observations

Alembic Pharmaceuticals received 8 USFDA approvals in Q3FY24

The company has received five final approvals

Pradeep Chakravarty joins Alembic Pharmaceuticals as Head - Global Quality

Prior to joining Alembic, he was working with Lupin Limited for more than 11 years

Alembic received 6 USFDA approvals during Q2FY24

The company has received six final approvals that includes Chlorpromazine Hydrochloride Tablets

Alembic Pharmaceuticals receives USFDA approvals for 5 products in Q1FY24

Alembic has a cumulative total of 184 ANDA approvals (159 final approvals and 25 tentative approvals) from USFDA.

Alembic Q4 FY23 consolidated PAT up at Rs. 48.25 Cr

Alembic has reported total income of Rs. 39.15 crores during the period ended March 31, 2023

Alembic Pharmaceuticals posts Q4FY2023 consolidated PAT at Rs. 152.60 Cr

The company has reported total income of Rs. 1407.34 crores during the period ended March 31, 2023

Alembic receives USFDA final approval for Brimonidine Tartrate Ophthalmic Solution

Brimonidine Tartrate Ophthalmic Solution is an alpha adrenergic receptor agonist indicated for the reduction of elevated intraocular pressure